Excellent
Mostly Aligned
Patient Risk:
Low
Summary
The AI response’s claim of an IV-only route restriction is directly and consistently supported by the provided FDA label text (Section 2 and additional route statements), with no contradictions identified.
Category Scores
Accurate Statements
For intravenous use only (IV-only route restriction)
Supported: Section 2 states “intended for intravenous use only,” and additional route language includes “For Intravenous Use Only” / “For Intravenous Infusion.”
The label includes additional route statements (“For Intravenous Use Only” / “For Intravenous Infusion”) and other sections reference intravenous administration.
Supported by the provided label excerpts: Section 4 references “Intravenous magnesium,” and Section 12 describes onset with “intravenous administration.”
Unsupported Statements
Contradictions
Important Omissions
Safety Assessment
Potential Patient Risk:
Low
The evaluated claim is a route restriction that is explicitly stated in the provided labeling; the response does not add dosing or safety details beyond what was cited.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Suggested Improvement